SBIR/STTR Research Award
Accelerator mass spect. carcinogen & Anti-Cancer Markers
Award amount
$203,954Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NEWTON SCIENTIFIC, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: (provided by applicant)
The goal of this program is to develop accelerator mass spectrometry (AMS) as
an analytical tool for cancer research, specifically for tracing the
interactions of carcinogens and cancer chemotherapeutic drugs with their
biomolecular targets. AMS is a highly selective means for detecting and
quantifying 14C in labeled biological samples, achieving a measurement
sensitivity up to seven orders of magnitude greater than decay counting.
Using AMS, 14C tracer studies may be conducted with less administered isotope
and with smaller samples containing lower concentrations of isotope than
previously possible. Newton Scientific, Inc. and collaborators at the
Massachusetts Institute of Technology have developed a compact, low-energy AMS
system designed specifically for analysis of biomedical samples. This
instrument incorporates a unique continuous-flow interface that allows direct
introduction of volatile organic compounds as well as gaseous CO2. The AMS
instrument has been interfaced to a standard gas chromatograph, and the
development of a liquid chromatograph interface is ongoing. Samples can also
be introduced into the AMS as CO2 obtained from off-line oxidation of tissue
samples.
Phase I of this program is dedicated to bringing the recently constructed AMS
instrument to the operational level required for use in tracer studies of
carcinogens and chemotherapeutic agents and to using the instrument in
proof-of-principle experiments with model compounds. In Phase II, we expect to
undertake pilot studies in an ongoing anti-cancer drug development effort at
MIT.
PROPOSED COMMERCIAL APPLICATION:
The biomedical 14C-AMS system used in this program will have widespread commercial
applications in the molecular analysis of cancer. With this instrument, it will be possible
to conduct studies of carcinogens, mutagens, toxins, and cancer therapeutics using
many orders-of-magnitude less tracer activity than is possible today. A potentially
important application of AMS is in the area of new durg research. The cost, size and
operating requirements of the complete biomedical AMS system will be compatible with
installation at major biomedical research centers.
Technology keywords
Not reported